Threshold Pharmaceuticals Inc. (THLD)
-NasdaqCM | Prev Close: | 5.44 |
|---|
| Open: | N/A |
|---|
| Bid: | 5.17 x 300 |
|---|
| Ask: | 5.76 x 400 |
|---|
| 1y Target Est: | 13.25 |
|---|
| Beta: | 3.5 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.95 - 9.28 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 597,613 |
|---|
| Market Cap: | 307.62M |
|---|
| P/E (ttm): | 8.62 |
|---|
| EPS (ttm): | 0.63 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Market Caps With Exceptionally High ROICat Seeking Alpha(Wed, May 22)
- THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, May 20)
- THRESHOLD PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 10)
- Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor ConferencesMarketwired(Thu, May 9)
- Are These The Biotech Stars Of Tomorrow?StreetAuthority Network(Thu, May 2)
- Threshold Pharmaceuticals Reports First Quarter 2013 Financial and Operational ResultsMarketwired(Thu, May 2)
- THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Thu, May 2)
- Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billionat Seeking Alpha(Mon, Apr 29)
- Threshold Pharmaceuticals Announces Presentation and Webcast at the 12th Annual Needham Healthcare ConferenceMarketwired(Thu, Apr 25)
- Threshold: My Biotech Pick Of The Yearat Seeking Alpha(Tue, Apr 23)
- 3 Biotechs And The Feuerstein-Ratain Ruleat Seeking Alpha(Tue, Apr 9)
- Following The Crashing Biotechs - 4 Stocks Ready For Springat Seeking Alpha(Mon, Apr 8)
- SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Threshold Pharmaceuticals Inc.PR Newswire(Wed, Apr 3)
- Threshold Pharmaceuticals Announces Presentation and Webcast at the 20th Annual Future Leaders in the Biotech Industry ConferenceMarketwired(Mon, Apr 1)
- Is Anything Left for Ziopharm Investors?at Motley Fool(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 36.03 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.56 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Threshold Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of drugs targeting the severe hypoxia in the microenvironment of solid tumors and the bone marrows of patients with hematological malignancies.
View More